Cepheid Reports Fourth Quarter And Full Year 2015 Results

Go back to Cepheid Reports Fourth Quarter And Full Year 2015 Results

Leerink Partners Reiterates Market Perform on Cepheid (CPHD) Following 4Q

February 3, 2016 8:51 AM EST

Leerink Partners reiterated a Market Perform rating on Cepheid (NASDAQ: CPHD), and cut the price target to $33.00 (from $39.00), following the company's 4Q earnings report. CPHDs reported revenue of $147M was in-line with the Street's forecast of $147M. Higher-than-consensus clinical systems sales were offset... More

Cepheid (CPHD) Reports Q4 EPS of 7c, Offers FY16 Guidance

February 2, 2016 4:15 PM EST

Cepheid (NASDAQ: CPHD) reported Q4 EPS of $0.07, may not compare to the analyst estimate of ($0.20). Revenue for the quarter came in at $147 million versus the consensus estimate of $146.91 million.

GUIDANCE:

Cepheid sees FY2016 EPS of $0.22-$0.28, may not compare to... More